[1] 刘虹霞.老年糖尿病药物的治疗进展[J].糖尿病新世界,2014(18):12-13.

[2] Suggested citation:American Diabetes Association.Older adults.Sec.10.In Standards of Medical Care in Diabetesd 2015[J].Diabetes Care, 2015,38(Suppl1):S67-S69.

[3] Selvin E,Parrinello CM,Sacks DB,et al.Trends in prevalence and control of diabetes in the United States,1988-1994 and 1999-2010[J].Ann Int Med, 2014,160(8):517-525.

[4] Migdal A,Yarandi SS,Smiley D,et al.Update on diabetes in the elderly and in nursing home residents[J].J Am Med Dir Assoc,2011,12(9):627-632.e2.

[5] Currie CJ,Peters JR,Tynan A,et al.Survival as a function of HbA1c in people with type 2 diabetes:a retrospective cohort study[J].Lancet, 2010,375(9713): 481-489.

[6] Huang ES,Liu JY,Moffet HH,et al.Glycemic control,complications,and death in older diabetic patients:the diabetes and aging study[J].Diabetes Care, 2011,34(6):1329-1336.

[7] Sanon VP,Sanon S,Kanakia R,et al.Hypoglycemia from a cardiologist's perspective[J].Clin Cardiol, 2014,37(8):499-504.

[8] Kimbro LB,Mangione CM,Steers WN,et al.Depression and all-cause mortality in persons with diabetes mellitus:are older adults at higher risk? Results from the Translating Research Into Action for Diabetes Study[J].J Am Geriatr Soc, 2014,62(6):1017-1022.

[9] 刘铜华.老年糖尿病的临床特点与合理用药[A].中国药学会学术年会暨第八届中国药师周报告集[C].2008:57-59.

[10] 刘铜华.老年糖尿病的临床特点与中西药联合应用[J].中华中医药杂志,2009,24(8):1038-1041.

[11] 中国老年学会老年医学会老年内分泌代谢专业委员会,老年糖尿病诊治措施专家共识编写组.老年糖尿病诊疗措施专家共识(2013年版)[J].中华内科杂志,2014,53(3):243-251.

[12] Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency[J]. Diabetes Care, 2011,34(6):1431-1437.

[13] Sinclair A,Morley JE,Rodriguez-Mañas L,et al.Diabetes mellitus in older people:position statement on behalf of the International Association of Gerontology and Geriatrics(IAGG),the European Diabetes Working Party for Older People (EDWPOP),and the international task force of experts in diabetes[J]. J Am Med Dir Assoc, 2012,13(6):497-502.

[14] Kirkman MS,Briscoe VJ,Clark N,et al.Diabetes in older adults: a consensus report[J].J Am Geriatr Soc,2012,60(12):2342-2356.

[15] Gooben K,Gräber S.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus:systematic review and meta-analysis[J].Diabetes Obes Metab, 2012,14(12):1061-1072.

[16] Thearle M,Brillantes AM.Unique characteristics of the geriatric diabetic population and the role for therapeutic strategies that enhance glucagon-like peptide-1 activity[J].Curr Opin Clin Nutr Metab Care, 2005,8(1):9-16.

[17] American Geriatrics Society 2012 Beers Griteria Update Expert Panel. American Geriatrics Society update beers criteria for potentially inappropriate medication use in older adults[J]. J Am Geriatr Soc,2012,60(4):616-631.

[18] Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes:a systematic review and metaanalysis[J]. Ann Intern Med, 2013,159(4):262-274.

[19] Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials[J]. Diabetes Obes Metab, 2014,16(5):457-466.

[20] Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis[J]. Diabetes Obes Metab, 2014,16(5):410-417.

[21] Diamant M, Nauck MA, Shaginian R, Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes[J]. Diabetes Care, 2014, 37(10):2763-2773.

[22] Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis[J]. Lancet, 2014,384(9961):2228-2234.

[23] Gough SC,Harris S,Woo V,et al.Insulin degludec:overview of a novel ultra long-acting basal insulin[J].Diabetes Obes Metab, 2013,15(4):301-309.

[24] Ismail-Beigi F,Moghissi E,Tiktin M,et al.Individualizing glycemic targets in type 2 diabetes mellitus:implications of recent clinical trials[J]. Ann Intern Med, 2011,154(8):554-559.

[25] Buse JB,Wolffenbuttel BH,Herman WH,et al.The Durability of Basal versus Lispro mix 75/25 insulin Efficacy(DURABLE)trial:comparing the durability of lispro mix 75/25 and glargine[J].Diabetes Care,2011,34(2):249-255.

[26] Eli Lilly and Company.Comparison of the efficacy and safety of two insulin intensification strategies[EB/OL].http://clinicaltrials.gov/show/NCT01175824,2014-06.

[27] Rosenstock J,Ahmann AJ,Colon G,et al.Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents:prandial premixed(insulin lispro protamine suspension/lispro)versus basal/ bolus(glargine/lispro)therapy[J].Diabetes Care,2008,31(1):20-25.

[28] 中华医学会内分泌学分会.预混胰岛素临床应用共识[J].药品评价,2013,10(11):33-38.

[29] 周 迪,鹿 斌.中国血糖监测临床应用指南(2011年版)解读[J]. 上海医药,2012,33(4):6-9.

[30] 中华医学会糖尿病学分会.中国血糖监测临床应用指南(2011年版)[J].中华医学杂志,2011,91(10):656-664.

[31] Morley JE,Sinclair A.Individualising treatment for older people with diabetes[J].Lancet,2013,382(9890):378-380.

[32] Arauz-Pacheco C,Parrott MA,Raskin P,et al.Hypertension management in adults with diabetes[J].Diabetes Care,2004,27(Suppl1):S65-S67.

[33] Schall P,Wehling M.Treatment of arterial hypertension in the very elderly:a meta-analysis of clinical trials[J].Arzneimittelforschung,2011,61(4):221-228.

[34] 戴 靖,郭立新.2013国际糖尿病联盟老年2型糖尿病管理指南解读[J].中国医学前沿杂志:电子版,2014,6(2):98-102.

[35] Cholesterol Treatment Trialists'(CTT)Collaboration,Baigent C,Blackwell L,et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170000 participants in 26 randomised trials[J].Lancet,2010,376(9753):1670-1681.

[36] Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus report[J]. Diabetes Care, 2012, 35(12): 2650-2664.

[37] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,6(7):447-498.

[38] International Diabetes Federation. IDF Diabetes Atlas[S]. 6th ed. Belgium:Brussels, 2013.